Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 21 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Weight regain after weight loss is a major problem in the treatment of persons with obesity. METHODS: In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed. RESULTS: After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, -4.1 kg (95% confidence interval [CI], -7.8 to -0.4; P = 0.03); in the liraglutide group, -6.8 kg (95% CI, -10.4 to -3.1; P<0.001); and in the combination group, -9.5 kg (95% CI, -13.1 to -5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, -5.4 kg; 95% CI, -9.0 to -1.7; P = 0.004) but not liraglutide (-2.7 kg; 95% CI, -6.3 to 0.8; P = 0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (-1.7 percentage points; 95% CI, -3.2 to -0.2; P = 0.02) and the liraglutide group (-1.9 percentage points; 95% CI, -3.3 to -0.5; P = 0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group. CONCLUSIONS: A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone. (Funded by the Novo Nordisk Foundation and others; EudraCT number, 2015-005585-32; ClinicalTrials.gov number, NCT04122716.).
Overview
CoChat Summary
## TL;DR
In this randomized, placebo-controlled trial of adults with obesity who first lost weight on an 8-week low-calorie diet, exercise plus liraglutide maintained weight loss better than either treatment alone. The combination also produced broader metabolic benefits, including improved body-fat percentage, glycated hemoglobin, insulin sensitivity, cardiorespiratory fitness, and physical functioning.
## Key findings
- After the 8-week low-calorie diet, 195 participants had a mean body-weight decrease of 13.1 kg; these participants were randomized to 1 year of treatment.
- At 1 year, compared with placebo, mean weight change differed by -4.1 kg with exercise, -6.8 kg with liraglutide, and -9.5 kg with the combination.
- The combination reduced body-fat percentage by 3.9 percentage points, versus -1.7 percentage points compared with exercise and -1.9 percentage points compared with liraglutide; it was the only strategy associated with improvements in glycated hemoglobin, insulin sensitivity, and cardiorespiratory fitness.
- Mean total weight loss from baseline to end of trial was 15.7% in the combination group, 10.9% with exercise, 13.4% with liraglutide, and 6.7% with placebo.
## Methods
- Investigator-initiated, randomized, head-to-head, placebo-controlled trial at Hvidovre Hospital and the University of Copenhagen; participants were randomized in a 1:1:1:1 ratio after an 8-week 800-kcal/day low-calorie diet.
- Sample: adults 18 to 65 years with obesity (BMI 32 to 43) and no diabetes; 215 started the diet and 195 (those losing at least 5% of baseline weight) were randomized.
- Main analysis used an intention-to-treat repeated-measures linear regression model with time, group, sex, age group, and time-by-group interaction; prespecified supplementary analyses included per-protocol, adjustment for initial weight loss, and multiple imputation.
## Limitations
- The paper states results may not be generalizable to older persons (>65 years), persons with BMI >43, patients with type 2 diabetes, or persons with low adherence to moderate-to-vigorous exercise or limited ability to exercise.
- The authors note that some participants missed the week-52 assessment: 166 of 195 (85%) attended the primary endpoint visit.
- Evident from the text: the trial was conducted in Denmark at two sites and in participants who first achieved at least 5% weight loss on a low-calorie diet, so applicability to broader obesity populations and to people unable to lose weight initially is not directly tested.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 1 Not valid · 3 Not checked · 76 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“and to increased appetite. 9-11”
What the sources say
- Not checked — no full text of the sourcecites [9] matched to “Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36” (2016) source
- Not checked — no full text of the sourcecites [10] matched to “Long-term persistence of hormonal adaptations to weight loss” (2011) source
- Partly supportedcites [11] matched to “Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss” (2015) sourceExperimental — accuracy not yet measured
The Introduction says that increased hunger and reduced satiety after weight loss are among the mechanisms favoring weight regain. It does not say that the regain is rapid, so the claim’s timing is unsupported. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Diet management programs, including the use of low-calorie mealreplacement products, can sustain low-calorie diet-induced weight loss with a small weight regain. 11,15-17”
What the sources say
- Supportedcites [11] matched to “Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss” (2015) source
The Study design describes a dietician-supported maintenance program that allowed low-calorie meal replacements after an initial very low-calorie diet. The Discussion reports that both groups maintained an approximately 12-kg loss over one year, with weight regain of 0.4 kg in the GLP-1RA group and 2.3 kg in the control group. (LLM, conf=0.90)
- Supportedcites [15] matched to “Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial” (2018) source
The Procedures describe a low-energy formula diet followed by food reintroduction and a structured weight-loss maintenance programme. The Results report that participants who engaged lost 14.5 kg during diet replacement, then regained 1.0 kg during food reintroduction and 1.9 kg during weight-loss management. These findings support the claim for this programme in people with type 2 diabetes; page numbers were not supplied. (LLM, conf=0.91)
- Supportedcites [16] matched to “Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial” (2018) source
The Methods (Interventions; page not provided) describe an 810 kcal/day programme using formula food products, followed by a weight-maintenance phase. The Results (Table 2; page not provided) show that mean weight loss in the treatment group was 15.1 kg at six months and 10.7 kg at 12 months: some weight was regained, but substantial weight loss remained. The Discussion (Implications of this research; page not provided) likewise reports average regain after the programme ended while noting that participants maintained clinically important losses. (LLM, conf=0.87)
- Supportedcites [17] matched to “Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial” (2019) source
The Study design and participants section describes an initial low-calorie formula diet followed by structured weight-maintenance support, including meal replacement when weight was regained. The Results report that the intervention group remained an average of 7.6 kg below baseline at 24 months, despite an average 2.6 kg regain between months 12 and 24. Page numbers are not available in our copy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Furthermore, lifestyle interventions that encourage increased physical activity concurrent with calorie restriction have been shown to sustain moderate weight loss. 18,19”
What the sources say
- Supportedcites [18] matched to “Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes” (2013) source
The Methods > Interventions passage describes a program combining reduced caloric intake with increased physical activity. The Results > Weight, Waist Circumference and Fitness and Discussion passages report that participants maintained a modest average weight loss of 6.0% at the end of the trial, supporting the claim for overweight or obese adults with type 2 diabetes. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [19] matched to “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin” (2002) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, the isolated benefits of exercise to prevent weight regain after weight loss is understudied. 20”
What the sources say
- Partly supportedcites [20] matched to “Is regular exercise an effective strategy for weight loss maintenance?” (2018) sourceExperimental — accuracy not yet measured
Section 2.1 (page unavailable) says randomized trials lack convincing evidence that exercise improves weight-loss maintenance, supporting uncertainty about its benefit. But it also discusses numerous trials and does not say that the isolated benefit of exercise, as distinct from other interventions, has been understudied. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This is more than the total weight losses of approximately 10% that were obtained with 1-year diet-management programs after an initial low-calorie diet. 11,15,16,29”
What the sources say
- Supportedcites [11] matched to “Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss” (2015) source
The Methods describe an initial 8-week very-low-calorie diet followed by a 52-week weight-maintenance program. The Results report an initial 12% weight loss (about 12 kg) and a 2.3 kg regain in the control group after 52 weeks, leaving approximately 10% total weight loss. The cited paper therefore supports the comparison with a roughly 10% loss after a year of diet management. (LLM, conf=0.90)
- Supportedcites [15] matched to “Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial” (2018) source
The Procedures section describes an initial low-energy total diet replacement phase followed by food reintroduction and ongoing weight-loss maintenance. Table S1 (Additional information) reports a 9.9% mean weight loss in the intervention group at 12 months, supporting the cited figure of approximately 10%. The 16% loss with the combination is the citing paper’s comparison, not a result attributed to DiRECT. (LLM, conf=0.92)
- Supportedcites [16] matched to “Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial” (2018) source
The Methods (Interventions; page unavailable) describe an initial 810 kcal/day total diet replacement followed by food reintroduction and weight-maintenance support. The Results (Primary outcome and baseline characteristics; page unavailable) report a mean loss of 10.7 kg at 12 months from a mean starting weight of 107.9 kg in that group—approximately 10%. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [29] matched to “Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial” (2020) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
42 more claims · 2 with their cited sources checked
Create a free account to see all 92 claims and every source verdict.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 21
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the overall weight loss was also minimal, since the study was focused on the weight-maintenance period following active weight loss.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Only those in the combined therapy group showed sustained improvements in glycated hemoglobin levels, insulin sensitivity, and cardiorespiratory fitness at the 1-year follow-up in the trial.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Only those in the combined therapy group showed sustained improvements in glycated hemoglobin levels, insulin sensitivity, and cardiorespiratory fitness at the 1-year follow-up in the trial.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“The combination group had a substantial weight reduction of −12.1 kg compared with placebo26, which might in itself increase appetite6.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Weight loss was maintained in the exercise group with a treatment effect of −5.3 kg compared with placebo26.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
41 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Diarrhea 38 (19) 4 (8) 7 (15) 13 (27) 14 (29)”
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657 · cited 4×
“Abdominal pain 46 (24) 3 (6) 13 (27) 18 (37) 12 (24)”
InfluentialMatsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735 · cited 4×
“Adverse event that led to the discontinuation of liraglutide or placebo 5 (3) 0 3 (6) 1 (2) 1 (2)”
BackgroundInfluentialA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Ross, R., Blair, S. N., Arena, R., Church, T. S., Després, J.-P., Franklin, B. A., Haskell, W. L., Kaminsky, L. A., Levine, B. D., Lavie, C. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000461 · Cited by 2,486
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 2×
“Diarrhea 38 (19) 4 (8) 7 (15) 13 (27) 14 (29)”
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012 · cited 7×
“Serious adverse event† 16 (8) 2 (4) 4 (8) 6 (12) 4 (8)”
Influential
Cited by
Items 301–400 of 526
Advancing Physical Function Outcomes in Glucagon-Like Peptide-1 Receptor Agonist Trials
Karregat, J. H. M., Phillips, S. M., Hopman, M. T. E., Eijsvogels, T. M. H., & Kambič, T. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-03519 · Cited by 3
Zhang, Y., Zhang, C., gong, X., cheng, P., Fu, H., Diao, L., & Song, C. (2026) · European journal of medical research · doi:10.1186/s40001-026-03933-9 · Cited by 13
“Three studies were treated with semaglutide (SME) [28–30], three with LIR [31–33], one with SME or LIR [34], one with oral semaglutide (OSM) [35], one with orforglipron (ORF) [36], two with tirzepatide (TZP) [37, 38] and one with retatrutide (RET) [39].”
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Hitaka, K., Sugawara, T., Matsumoto, M., & Nio, Y. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02025-2 · Cited by 3
“In some cases, the discontinuation of GLP-1 therapy can result in weight regain due to a rebound effect [43, 44].”
Raun, S. H., Pham, T. C. P., Viggars, M. R., Ato, S., Takagaki, Y., Yan, Z., Bock, K. D., Hornberger, T. A., Richter, E. A., Auwerx, J. H., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.03.005 · Cited by 5
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Is weight cycling clinically harmful?
Magkos, F., & Stefan, N. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00037-9 · Cited by 4
Ilie, I. R. P., Ghibu, S., Butucă, A., Dobrea, C. M., Frum, A., Homorodean, C., Chiş, A. A., & Morgovan, C. (2026) · Pharmaceuticals · doi:10.3390/ph19060876 · Cited by 7
Jobanputra, R., Sargeant, J. A., Plekhanova, T., James, E., Almaqhawi, A., Webb, D. R., Davies, M. J., & Yates, T. E. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70194 · Cited by 10
Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps
Dubin, R. L., Sanders, T. N., Schwab, H. M., Heymsfield, S. B., & Greenway, F. L. (2026) · Obesity · doi:10.1002/oby.70212 · Cited by 3
Efficacy of Dapagliflozin Combined with Lifestyle Intervention in Obesity Control
Dai, W., & Qiao-lin, P. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/7745873 · Cited by 3
“Studies have shown that both dapagliflozin and life intervention therapy alone can effectively reduce blood lipid levels in obese patients [30, 31].”
BackgroundRetractedPharmacological treatment of obesity
Anglart, G., Dominiak, K., & Dettlaff, K. (2023) · Farmacja Polska · doi:10.32383/farmpol/161473 · Cited by 5
Obesity is South Africa’s new HIV epidemic
Chandiwana, N. C., Venter, F., Manne‐Goehler, J., et al. (2024) · South African Medical Journal · doi:10.7196/samj.2024.v114i4.1927 · Cited by 3
“[11] The Standard Treatment Guidelines and Essential Medicines List currently contains no approach to the disease of obesity, and medication and surgical approaches were removed from the 2023 National Obesity Strategy, which barely mentions treatment, apparently owing to cost.”
BackgroundByberg, S., Holt, J., Sandsdal, R. M., Holm, L. A., Madsen, L. B., Christensen, B., Jensen, S. B. K., Hansen, T. F., Holm, J., & Torekov, S. S. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-082446 · Cited by 4
“15 18 Thus, for youth who do not experience a reduction in adiposity following non-pharmacological care alone, the addition of GLP-1 RA may prove an effective strategy.”
Self-citationTakyi, A. K., Gaffey, R. H., & Shukla, A. P. (2025) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00465-1 · Cited by 4
“Prior research studies have provided considerable evidence of the beneficial effects of combining physical activity with GLP-1 receptor agonists to sustain weight loss [79–81].”
InfluentialZhang, J., Peng, J., Yu, C., Ning, Y., Lin, W., Ni, M., Xie, Q., Yang, C., Liang, H., & Lin, M. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101265 · Cited by 5
“…[4] (e.g., dapagli fl ozin [5] and empagli fl ozin [6]) primarily function by reducing glucose reabsorption and sodium levels, while glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide [7] and semaglutide [8]) affect glucose regulation and exhibit anti-in fl ammatory effects [9].”
Animal Models of Exercise and Cardiometabolic Disease
Dong, G., RYAN, T. E., & Esser, K. A. (2025) · Circulation Research · doi:10.1161/circresaha.124.325704 · Cited by 6
Proteomics reveals unique plasma signatures in constitutional thinness
Cominetti, O., Galindo, A. N., Corthésy, J., Carayol, J., Germain, N., Galusca, B., Estour, B., Hager, J., Gheldof, N., & Dayon, L. (2022) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.202100114 · Cited by 2
Neu, C., Skitek, K., Kissler, H. J., Baumbach, P., Settmacher, U., Treml, R. E., & Coldewey, S. M. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062592 · Cited by 3
Alarfaj, S. J., Ibrahim, A. A. M., Alshahrani, J., Alnuwaysir, M., Almutairi, A., & Alwahhabi, B. K. (2022) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/wav0cpt0bt · Cited by 3
SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide
Frandsen, C. S., & Madsbad, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01292-8 · Cited by 3
Self-citationTkachenko, V. I., & Bagro, T. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.5.2023.1299 · Cited by 4
“The participation of these receptors in stressor mechanisms, regulation of eating behavior, metabolic processes, immune response has been proven [5], OX1R and OX2R are also peptides of the incretin gene, which includes glucagon-like peptide-1, the effectiveness of which in the treatment of obesity is increasing every…”
BackgroundPrecision weight management in people with knee osteoarthritis and overweight or obesity
Yuan, S., & Hunter, D. J. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01209-2 · Cited by 3
Ammar, O. F., Sharma, K., Liperis, G., Fraire-Zamora, J. J., Serdarogullari, M., Ali, Z. E., Ramasamy, R., Laurentino, S., Watkins, A. J., & Mincheva, M. N. (2023) · Human Reproduction · doi:10.1093/humrep/dead126 · Cited by 7
The outcome of a multicomponent lifestyle intervention in patients with obesity: A cohort study
Kierkegaard, S., Sørensen, U. M., Lange, L. B., Mortensen, L. S., & Bruun, J. M. (2023) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2023.102259 · Cited by 3
Kornerup, N., Danielsen, J. H., Sahl, R. E., Pico, M. L., Johansen, M. Y., Knop, F. K., Bønnelykke, K., Bergholt, T., Kelstrup, L., Foghsgaard, S., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-087895 · Cited by 2
Self-citationKim, K. M., Choi, J. H., Han, B., Hur, Y., Son, J. W., Nam, G. E., Kang, J., Cho, Y. J., Kim, W. J., & Lim, S. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16342 · Cited by 2
Xing, C., Fan, X., Liu, M., Chen, Y., Jia, J. M., Li, W., Hong, Y., & Zhou, J. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04412-z · Cited by 3
“Liraglutide, a synthetic, long-acting glucagon-like peptide-1 (GLP-1) analog is mainly used for the treatment of type 2 diabetes and obesity [22–24].”
Moetaz, I., AbuMweis, S. S., Alqadi, S., & Abughoush, M. H. (2025) · Clinical Obesity · doi:10.1111/cob.70030 · Cited by 2
Lingow, S. E., Carris, N. W., Clements, J. N., Courtney, L. A., Lennon, A., Sherrill, C. H., & Dril, E. V. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70111 · Cited by 5
Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies
Soliman, S., Andrews‐Dickert, R., Ročić, P., & Mitov, M. I. (2025) · Pharmaceuticals · doi:10.3390/ph18101519 · Cited by 3
“These findings suggest that GLP-1 RAs like liraglutide may reach a plateau in their effectiveness when used alone, targeting mechanisms that increase energy expenditure may complement GLP-1 RAs and result in additional weight loss [16].”
Choi, S. M., Lim, S. H., Lee, H. S., Choi, G., Kim, M. J., Kim, H. W., & Choi, C. (2025) · Pharmaceuticals · doi:10.3390/ph18121843 · Cited by 2
“Overeating occurs when satiety signaling is impaired and the feeding center is enhanced [50].”
Kuckuck, S., van Gerwen, N., Oosterman, J. E., Savas, M., Kavousi, M., Penninx, B. W. J. H., Boon, M. R., & van Rossum, E. F. C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70393 · Cited by 3
Wang, N., Guo, H., Song, L., Wang, J., Hu, S., Wang, M., Zhang, D., Jing, Y., Zhang, Y., Wang, M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70571 · Cited by 5
“5,6 However, limited evidence exists regarding the long-term metabolic consequences after withdrawal, particularly regarding how peripheral metabolic tissues and central appetite regulation differentially readapt.”
Puga, T. B., Box, M. W., Jen, A., Liu, Y., & Riehl, J. T. (2026) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2026.02.002 · Cited by 2
Ahmad, Y., Wasan, R., Perchik, J. D., & Nanda, N. C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124430 · Cited by 2
“A 2021 study demonstrated that compared to GLP-1 receptor agonist use alone, GLP-1 use in conjunction with moderate-to-vigorous intensity exercise can lead to improved healthy weight loss maintenance [92].”
Microbiota-driven gut-brain signaling underlies antidepressant effects of a GLP-1 analog
Bian, L., Cai, Y., Zhang, Y., Shen, L., Wang, H., Gao, F., Cai, N., Chen, W., You, C., Yang, Y., et al. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.05.003 · Cited by 4
Sandsdal, R. M., Holt, J., Alkhefagie, H. G. A., Jørgensen, J. R., Juhl, C. R., Olsen, L. M., Byberg, S., Thirumathyam, R., Gliemann, L., Stallknecht, B. M., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01554-4 · Cited by 3
“https://doi.org/10.1038/s42255-026-01554-4 than to the effects of liraglutide on metabolism alone during weight loss maintenance 11 .”
InfluentialSelf-citationVandoni, M., Gatti, A., Rossi, V., Giuriato, M., Pellino, V. C., Zuccotti, G., & Calcaterra, V. (2026) · Obesity Reviews · doi:10.1111/obr.70189 · Cited by 3
“While individual studies have explored this combination [28], the variability in protocols, populations, and outcome measures has limited the ability to draw clear conclusions regarding its efficacy.”
Adding liraglutide to diet and exercise to maintain weight loss – is it worth it?
Doggrell, S. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.2019707 · Cited by 3
“The authors also pointed out that major limitations of the study were that it cannot be extended to people older than 65 years of age, BMI over 43 kg/m(2), subjects with conditions such as type 2 diabetes, and people who will not adhere to exercise programs [1].”
BackgroundInfluentialBaden, C. S., Andersen, J. T., Christensen, M., & Gade, C. (2023) · Adverse Drug Reaction Bulletin · doi:10.1097/fad.0000000000000067 · Cited by 3
Incretin Analogs for Weight Management in Adults Without Diabetes
Lobkovich, A. M., Kale-Pradhan, P. B., & Lipari, M. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231190089 · Cited by 4
“28,29,31 27-32 , 37 One study specifically compared semaglutide vs 37 The most common adverse events reported by ≥ 10% of participants were mainly gastrointestinal in nature and included nausea, vomiting, diarrhea, and constipation as well as headaches.”
BackgroundResultInfluentialRole of Liraglutide Use in Patients With Heart Failure
Allam, S. R., Sartaj, S., Moquim, H., Husnain, M. A., Bustos, D., Lakkimsetti, M., Randhawa, A. K., & Gupta, I. (2023) · Cureus · doi:10.7759/cureus.50065 · Cited by 4
“Coincidentally, patients who experienced gallbladder-related complications also experienced a greater mean decrease in weight [15].”
BackgroundInfluentialLiraglutide does not increase heart rate of diabetic patients during acute myocardial infarction
Li, Q., Wu, C., Sun, S., Yang, L.-C., Li, Y., Niu, Y., Zhang, L., Li, W., & Yu, Y. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13517 · Cited by 1
“10,13,17,18,21,22 We supposed that this difference was influenced by heart function.”
BackgroundXu, J., Xu, H., Yang, F., Xie, Y., Cai, F., Mao, S., Lu, M., Zhuang, H., & Hua, Z. (2024) · MedComm · doi:10.1002/mco2.641 · Cited by 3
Bloomgarden, Z. T. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.70025 · Cited by 3
Advances in Discovery and Design of Anti-influenza Virus Peptides
Li, S., Xie, X., Zhou, S., & He, J. G. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673325318241004100506 · Cited by 2
Ferreira, E. V. M., Oliveira, R. K. F., Salomão, R., Brunialti, M. K. C., Cardoso, M. B. A., Chen, C.-N., Zhao, L., & McCabe, C. (2025) · Infectious Disease Reports · doi:10.3390/idr17010005 · Cited by 2
Lindahl, M., Mortensen, G. L., Larsen, M., Thrysøe, P., Bach, C. N., Geert-Jørgensen, A., Mathiesen, T. W., Gulstad, K. N., Noer, B. R., Fogstrup, I. H., et al. (2025) · European Journal of Physiotherapy · doi:10.1080/21679169.2025.2519345 · Cited by 2
“…factors [6]. supervised exercise significantly supports weight loss maintenance after the medica-tions’ termination compared to termination alone [7,8]. it is, therefore, essential that WRD users adopt and maintain a physically active lifestyle. counselling about physical activity and diet was…”
Drugs Based on Bioactive Oligopeptides
Ledenev, O. V., Levitskaya, O. V., & Syroeshkin, A. V. (2025) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v15i6.7194 · Cited by 2
Liraglutide and Exercise: A Possible Treatment for Obesity?
Macêdo, A. P. A., Vieira, R. F. L., Brisque, G. D., Abud, G. F., & Pauli, J. R. (2022) · Obesities · doi:10.3390/obesities2030023 · Cited by 3
“[13], participants underwent an 8-week intervention with a low-calorie diet, which promoted a reduction in body weight and fat percentage.”
BackgroundPronk, N. (2024) · ACSMʼs Health & Fitness Journal · doi:10.1249/fit.0000000000000992 · Cited by 2
Liraglutide attenuates post-cardiac arrest brain injury by inhibiting autophagy and ferroptosisPreprint
Xing, C., Tang, L., Li, S., Yang, C., Feng, J., Jia, J., Chen, Y., Wang, M., & Zhou, J. F. (2023) · Research Square · doi:10.21203/rs.3.rs-2858822/v1 · Cited by 2
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 2
Timing of physical activity in the pursuit of fat mass loss and weight maintenance
Schönke, M., & Rensen, P. C. N. (2024) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2024.100542 · Cited by 1
GLP-1 and GIP analogues in the treatment of obesity
Jasińska-Balwierz, A., Balwierz, R. J., Biernat, P., Makieieva, N., Tomków, M., Cesarz, K., Osowski, M., Dorożyński, B., Skotnicka-Graca, U., & Lipok, J. (2024) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2024.0023 · Cited by 2
Mohammed, S., Shahin, M. A. H., Alamoudi, F. A., Morshed, M. M., Ali, W. G. M., & Shaaban, A. E. A. (2025) · Healthcare · doi:10.3390/healthcare13091023 · Cited by 3
“However, studies indicate that weight regain is probable over time, primarily due to difficulty sustaining new lifestyle changes for an extended period [6,10,11].”
Filha, A. M. S. G., Leite, J. M., Lagares, L. S., de Jesus, D. S., Bomfim, E. S., de Almeida, L. A. B., Pinto, L. L. T., de Souza, L. A. J., & dos Santos, C. P. C. (2025) · Brazilian Journal of Kinanthropometry and Human Performance · doi:10.1590/1980-0037.2025v27e103939 · Cited by 5
Ennour‐Idrissi, K., Laforest, S., Tchernof, A., Durocher, F., & Diorio, C. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01814-5 · Cited by 1
“In fact, the overview of results from previous studies on the effect of physical activity and diet suggests that both have an effect on adiposity, with a much stronger effect of diet than physical activity, and that these effects are additive [72 – 74].”
Cardiometabolic risk effects of weight‐loss medications: An updated network meta‐analysis
Wang, D., Diao, H., Sun, W., Huan, W., Wang, Y., Ding, L., Cui, W., & Ma, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16585 · Cited by 3
Коморбидность ожирения и сердечно-сосудистых заболеваний: пути преодоления проблемы
Суджаева, О. А. (2025) · Кардиология в Беларуси · doi:10.34883/pi.2025.17.3.007 · Cited by 1
Alpert, Z., Katzman, J. L., Lajam, C. M., Schwarzkopf, R. M., & Rozell, J. C. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.08.068 · Cited by 2
Péč, M. J., Jurica, J., Péčová, M., Nagy, N., Focko, B., Miertová, Z., Ferencová, N., Ságová, I., Tonhajzerová, I., Bolek, T., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18091364 · Cited by 4
Multivalent Protein Nanorings for Broad and Potent SARS‐CoV‐2 Neutralization
Behbahanipour, M., Goldin, C. J., Prato, C. A., Paletta, A. L., Bárcenas, O., Navarro, S., Pujols, J., Murgida, D. H., Tribulatti, M. V., Esperante, S., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503487 · Cited by 2
Evaluation of leptin treatment on maintenance of body weight loss in diet‐induced obese mice
Breen, D. M., Saavedra-Peña, R. D. M., Joaquim, S., Kong, J., Reese, R., Kuzmiski, J. B., Stansfield, J. C., Jones, R., Bence, K. K., & Jackson, V. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70207 · Cited by 2
“49,50 Again, treatment with r-Leptin or Fc-Leptin was not sufficient to maintain weight loss compared to vehicle control (Figure 3D,E).”
Reid, K. F., & Bhasin, S. (2025) · Frontiers in Aging · doi:10.3389/fragi.2025.1640030 · Cited by 4
Glucagon-like Peptide-1 Agonists and Exercise for Weight Reduction: A Review of Current Evidence
Owaidat, J. F., Zuaiter, S., Daseh, A. I., Nemrawi, F. A. A., Abu‐Jeyyab, M., & Al-Jafari, M. (2025) · JAP Academy Journal · doi:10.4103/japaj.japaj_5_24 · Cited by 1
Saraiva, J. F. K., Valério, C. M., Rached, F. H., van de Sande‐Lee, S., Rocha, V. Z., Valente, F., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250621 · Cited by 17
“37 • Ensaios clínicos randomizados (ECRs) que avaliaram medicamentos com efeito moderado na perda de peso, como sibutramina, 38 liraglutida 39 e a combinação bupropiona + naltrexona, 40 demonstraram que a combinação com MEV apresentou melhores resultados em relação à redução de peso corporal e de…”
Avian GCGR-mediated continuous fat utilization offers perspectives for obesity treatment
Zhang, C., Wang, X., Feng, C., Zheng, H., Leng, S., Jiang, Y., Sun, Q., Li, X., Zhang, T., Zhang, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66305-7 · Cited by 1
“Current obesity treatments based on glucagon receptor family are mostly by ligand application, such as liraglutide or semaglutide 74,75 .”
Exercise maintains LEAP2 levels after weight loss in females with obesity
Holt, J., Holm, S. K., Sandsdal, R. M., Jensen, S. B. K., Juhl, C. R., Noer, M. H., Afshar-Bahadori, Y., Blond, M. B., Gerds, T. A., Stallknecht, B. M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114288 · Cited by 1
Self-citationSanchis‐Gomar, F., Neeland, I. J., Ruiz‐Lozano, P., Alnahar, O., & Rodríguez, F. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02334-4 · Cited by 1
“In an animal model, taldef-grobep alfa combined with semaglutide has been reported to enhance body composition, with notable decreases in adipose tissue and increases in LBM. demonstrated superior fat loss compared with either intervention alone, while preserving LBM [48].”
Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management
Riccioni, G., Notarangelo, C., Riccioni, M., & D’Orazio, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010354 · Cited by 1
Bæch‐Laursen, C., Ucin, J. V., Galsgaard, K. D., Llana, J., Kissow, H., Rehfeld, J. F., Holst, J. J., Pedersen, B. K., & Sanchís, P. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106152 · Cited by 3
“44 In the present study, increased physical activity tended to slow gastric emptying following a mixed meal test, but not following a glucose tolerance test.”
Self-citationExercise training for the prevention and treatment of cardiometabolic disease
Kong, S., Foulkes, S., & Peters, A. E. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001288 · Cited by 2
Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications
Lee, J., You, J. H., Park, H. J., Roh, J.-L., & Paek, S. H. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00709-4 · Cited by 3
“Most weight-loss interventions—including exercise [49], calorie restriction [ 50 ], cold exposure [51], and selected antidiabetic agents [ 10 , 52]—ultimately increase reliance on FAO, which supplies acetyl-CoA to sustain tricarboxylic acid (TCA) cycle activity and electron transport chain…”
Edens, E. S., Falise, H., Smith, R., & Bernardo, E. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70140 · Cited by 2
“One study established that regular exercise in combination with liraglutide was superior to GLP‐1 RA therapy alone in maintaining weight loss over a 1‐year period [18].”
Suzuki, R., Leith, A., Harrison, L., Tanizawa, Y., Urano, M., Yoshino, M., Artime, E., & Mount, J. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2652738 · Cited by 1
Adamidis, N., Margariti, T., Georgakopoulou, V., Adamidi, S., Desalermos, A. P., Kyventidou, M., Koutrakos, T., Bouros, D. E., Papadopoulou, N., & Adamidis, S. (2026) · Cureus · doi:10.7759/cureus.107081 · Cited by 3
Not All Weight Loss Is Equal: Towards Muscle‐Preserving Therapies in Obesity
Abraham, J. D., Khan, M. S., & Anker, S. D. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70298 · Cited by 1
“However, an important limitation of this beneficial weight loss is that not all weight loss is equal: 25%–40% of total weight loss may reflect skeletal muscle mass loss or other fat-free mass [1, 5–7].”
Joy, E., & Bonnet, J. P. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276261450530 · Cited by 1
Wachiraphansakul, N., Vongchaiudomchoke, T., Manosroi, W., Ruengorn, C., Noppakun, K., Ngamvichchukorn, T., Sood, M. M., Thavorn, K., Hutton, B., & Nochaiwong, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70884 · Cited by 2
Bruna-Mejías, A., Valenzuela‐Fuenzalida, J. J., Oyanedel-Amaro, G., Figueroa-Puig, J., Cabezas-Salgado, J. J., Orellana-Donoso, M., Cifuentes-Suazo, G., & Loro-Ferrer, J. F. (2026) · Nutrients · doi:10.3390/nu18111781 · Cited by 3
Sancho-Haro, E. S., Muñoz-López, M., Baz-Valle, E., Villanueva-Tobaldo, C. V., Tornero-Aguilera, J. F., López-Gil, J. F., López‐Moreno, M., Martín-Rodríguez, A., & Clemente‐Suárez, V. J. (2026) · Pharmaceuticals · doi:10.3390/ph19060897 · Cited by 2
Rakhsha, S. S., Shahinfar, H., Ebrahimi-Mousavi, S., Kosari, A., Aali, Y., Mirzababaei, A., Hosseini, S. A., Jadidi, P., Shafiee, G., Mansourzadeh, M. J., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70957 · Cited by 4
Busk‐Cirera, L., Carlsen, I. Ø., Madsen, L. B., Sandsdal, R. M., Jensen, E., Jensen, S. B. K., & Torekov, S. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71006 · Cited by 6
Self-citationOlumuyide, E. O., Ariel, K., & Aneni, E. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02143-x · Cited by 1
“Conversely, even modest reductions in contractile mass could be functionally consequential if muscle quality is not simultaneously improving.”
InfluentialChen, Z., Cheng, R., Wang, H., & Hu, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71083 · Cited by 2
Ruga, S., Matarese, E., Bava, R., Lombardi, C., Dimatteo, T., Miscio, L., Raponi, M., Giordano, A., Sansone, C., Liguori, G., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19081230 · Cited by 1
Stanton, L. A., Naqvi, J. B., Devaraj, S. M., McGuill, A., Norwood, T. A., & Linke, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71152 · Cited by 2
“Early GLP-1 combination studies suggest that physical activity (PA) that includes resistance training can enhance fat loss while preserving lean mass relative to GLP-1 therapy alone [15].”
InfluentialEffects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review
van Maren, S., van Doorn, E. P. M., Smits, M. M., Tack, C. J., van Rossum, E. F. C., & Messaoudi, S. E. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02073-3 · Cited by 1
Nur mit Kalorien zu jonglieren, greift bei Adipositas oft zu kurz
Blüher, M. (2021) · Info Diabetologie · doi:10.1007/s15034-021-3752-7 · Cited by 1
“Eine Gruppe machte ein moderat-intensives Trainingsprogramm allein, eine zweite machte dies in Kombination mit Liraglutid 3 mg/d, eine dritte steigerte ihre körperliche Aktivität nur moderat und erhielt Liraglutid 3 mg/d zusätzlich, die Kontrollgruppe ging zurück in ihren Alltag [14].”
BackgroundManagement of Obesity through Diet and Exercise
Jamil, K., Baqir, S. R., Fahim, M. F., Lata, P., Khan, B., & Aziz, M. (2023) · DIET FACTOR (Journal of Nutritional & Food Sciences) · doi:10.54393/df.v4i03.87 · Cited by 3
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
Ni, D., Kokkinos, P. F., & Nylén, E. (2024) · Military Medicine · doi:10.1093/milmed/usae311 · Cited by 1
Yu, H., Feng, N., Zhong, W., Han, Y., Cheng, Y., Zhang, Z., Wang, Y., Gao, P., Huang, R., Zhang, C., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202402546r · Cited by 2
“22,41 To investigate whether liraglutide can reduce food intake and attenuate obesity in Nmnat2 ARC−/− mice, liraglutide was injected into Nmnat2 ARC−/− mice once a day at a dose of 0.7 mg/ kg body weight 12 days after bilateral injection of AAV- CMV- GFP-Cre once into ARC.”
InfluentialHow to keep weight off after obesity drugs
Dolgin, E. (2025) · Nature · doi:10.1038/d41586-025-01770-0 · Cited by 1
Berković, M. C., Cigrovski, V., & Ružić, L. (2025) · World Journal of Methodology · doi:10.5662/wjm.v15.i4.105462 · Cited by 5
Ткач, С. М., Pankiv, V. І., & Yuzvenko, Т. Y. (2023) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2023-1-47 · Cited by 2
Glucagon like peptide-1 receptor agonists in type 1 diabetes
Deng, C., Fan, W., & Li, X. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101487 · Cited by 1
Lokeshwar, S. D., Geada, A., & Ramasamy, R. (2022) · European Urology · doi:10.1016/j.eururo.2022.08.016 · Cited by 1
Metadata
- Authors
- Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., Jensen, J.-E. B., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital–Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) — all in Denmark.
- Amager Hospital (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-06
- Volume
- 384
- Issue
- 18
- Pages
- 1719-1730
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3158123746
- Cited by
- 536
- References
- 35
- Citations by year
- 2026: 140 · 2025: 137 · 2024: 86 · 2023: 78 · 2022: 71 · 2021: 23
- FWCI
- 37.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Funders
- Helse Fonden
- Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
- Danish Diabetes Academy
- Novo Nordisk Fonden (NNF15CC0018486, NNF16OC0019968)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, weight loss maintenance, weight regain, liraglutide, physical activity, hypocaloric diet, body fat percentage, GLP-1 receptor agonists, combination therapy, metabolic health
- MeSH terms
- Liraglutide, Adipose Tissue, Adult, Combined Modality Therapy, Exercise Therapy, Female, Humans, Male, Middle Aged, Obesity, Weight Loss, Anti-Obesity Agents, Caloric Restriction, Body Size
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.